To study the role of plasma apo F, a reliable and sensitive tool for the quantification would be needed. Methods: We have developed a sandwich ELISA using two monoclonal antibodies for human plasma apo F, and analyzed apo F concentration in 397 Japanese healthy and 221 hypertriglyceridemic subjects. Results: Our ELISA enables apo F to be assayed in the range of 0.6-25 μg/mL with intra-and interassay coefficients of variation less than 3.8% and 7.8%, respectively. In healthy subjects, plasma apo F concentration was 12.5±2.9 μg/mL (mean±SD), and was significantly higher in females than in males (p＜0.05). By linear regression analysis in healthy subjects, plasma apo F concentration correlated positively with HDL cholesterol and apo A-I levels, and in males but not in females, negatively with apo B and triglyceride levels. It also correlated negatively with intrinsic CETP activity measured using intrinsic apo B-containing lipoprotein as an acceptor, and positively with PLTP mass and apo J levels. Apo F concentration in hypertriglyceridemic patients (10.3±3.1 μg/mL) was lower than in healthy controls (p＜0.0001) and correlated positively with PLTP mass. Conclusions: Our ELISA is reliable and sensitive for the quantification of plasma apo F concentration. This system can be applicable for clinical significance in lipoprotein metabolism and reverse cholesterol transport. 
Introduction
Apolipoprotein F (apo F) is a 29-kDa acidic gly-coprotein associated with LDL 1, 2) and HDL 3-5) in human and mouse plasma [6] [7] [8] . It is also known as a lipid transfer inhibitor protein (LITP) for its ability to inhibit lipid transfer among lipoproteins in vitro 1) . Apo F is an endogenous inhibitor of cholesteryl ester transfer protein (CETP)-mediated cholesteryl ester (CE), triglyceride (TG) and phosphatidylcholine (PC) transfers and phospholipid transfer protein (PLTP)-mediated PC transfer 1, 9, 10) . Apo F inhibits CETP Takeshi Kujiraoka and Takaaki Nakamoto contributed equally to this work.
(211 males, 186 females) without any medication, at BML Clinical Reference Laboratory (Saitama, Japan), and from 221 hypertriglyceridemic subjects (166 males and 55 females) at Dokkyo Medical University Nikko Medical Center, was collected after overnight fasting. EDTA-plasma was isolated immediately by centrifugation at 4 ℃ and stored at −80 ℃ until use. Lipid profiles are shown in Table 1 and 2. Healthy volunteers were not taking any medication. None of the hypertriglyceridemic subjects, who had hypertension (53%) and diabetes mellitus (26%), was taking lipid-lowering medication. In healthy subjects, concentrations of total and LDL cholesterol and TG were greater, and those of apo A-I and apo E were lower in males than in females. In hypertriglyceridemic subjects, there was no significant difference between the genders in the lipid parameters except for the HDL cholesterol level. This study was approved by the ethics committees of Dokkyo Medical University and BML. Informed consent was obtained from all subjects.
Cloning of Human Apo F and Expression of Recombinant Human Apo F
Human apo F cDNA was obtained by RT-PCR from mRNA of HepG2 cells as described elsewhere 13) . Briefly, PCR was carried out using 5'-gacggatcctccctcccgacagaggactgtgaga-3' as the sense primer and 5'-gacgaattctcagtgatggtgatggtgatgtatctcaagactcccagccccagga-3' as the antisense primer for apo F cDNA1 and 5'-gacggatcctccctcccgacagaggactgtgaga-3' as the sense primer and 5'-gacgaattctcagtgatggtgatggtgatgtatctcaagactcccagccccagga-3' as the sense anti-primer for apo F cDNA2.The apo F cDNAs encoded amino acids 165-326 and 1-326 for cDNA1 and cDNA2, respectively, and both cDNAs were constructed with a 6 x His tag at the C-terminus. The apo F cDNA1 was separately subcloned into the pQE-30 plasmid (Qiagen) to yield the pQE-30/apo F1 vector. Escherichia coli JM109 (Toyobo, Tokyo, Japan) bearing the pQE-30/apo F1 plasmid was cultured in TB medium containing 50 mg/L ampicillin at 37℃. Expression was induced with 1 mM isopropyl thiogalactopyranoside and, after 5 h, the cells were harvested by centrifugation. The cells suspended in phosphate buffer (50 mM sodium phosphate and 0.5 M NaCl, pH 8.0) were disrupted by sonication. The insoluble fraction was pelleted by centrifugation at 30,000 g for 30 min at 4 ℃, and the pellet was dissolved in phosphate buffer (pH 8.0) containing 7 M urea and 10 mM imidazole, followed by sonication. Then, the ultra-solubilized fraction was centrifuged at 30,000 g for 30 min at 4 ℃, and the supernatant was loaded onto a nickel-nitrilotriacetic activity by preventing CETP from binding to the lipoprotein surface 11) . By selective inhibition of lipid transfer to/from LDL, apo F enhances the net flux of CE from HDL to VLDL, facilitating the clearance of HDL-derived CE in the circulation and promoting reverse cholesterol transport (RCT).
Apo F mRNA is abundantly expressed in the liver and encodes a 22 amino acid signal peptide and 308 amino acids 4) . Plasma apo F is a 162 amino acid protein derived from the C-terminal portion of apo F proprotein by proteolytic cleavage at residues 146-147 (Arg/Ser). It contains one N-linked glycosylation site and numerous O-linked glycosylation sites, resulting in being acidic with an isoelectric point of 4.5 and 40% greater molecular mass than predicted 4) . Recent studies have shown that plasma apo F exists in two forms, one active and the other inactive 7) . Apo F bound to LDL has LTIP activity, whereas the HDL-associated apo F exists as part of the 470 kDa inactive complex. Although human apo F preferred to associate with the larger HDL particles in the gel filtration profile, apo F-containing particles show density in the HDL3 range 7, 8) . By immunoblotting analysis, plasma apo F associated with LDL was markedly higher in hypercholesterolemic subjects than in normolipidemic subjects, which was due to the distribution of apo F and its lipoprotein composition 11, 12) . The clinical significance in normolipidemic and dislipidemic subjects has also been studied in detail by a competitive enzyme immunoassay (EIA), and showed a decrease in the apo F level in hypertriglyceridemic males 2) . More recently, Lagor et al. have shown that mice overexpressing human CETP and apo F have a lipoprotein profile similar to human plasma, and decreased plasma HDL cholesterol due to the increased clearance of plasma HDL-CE 8) . They also found that the larger HDL isolated from mice overexpressing human apo F would be a potent acceptor for the efflux of cholesterol from macrophages. These results suggest that apo F plays an important role in lipoprotein metabolism and RCT.
In view of the possible importance of apo F in reverse cholesterol transport, we have developed a new sandwich ELISA and applied it to determine plasma apo F concentration in Japanese healthy and hypertriglyceridemic subjects, and its relation to plasma factors of lipoprotein metabolism.
Materials and Methods

Subjects
Blood from 397 apparently healthy volunteers gated anti-mouse IgG (Zymed Laboratories) as the second antibody. Bound antibodies were detected with an enhanced chemiluminescence kit (Perkin-Elmer).
Preparation of MAbs Against Apo F
Monoclonal antibodies (MAbs) against apo F were obtained as previously described [13] [14] [15] [16] . Balb/c mice were immunized with 25 μg purified rhapo F, and spleen cells from mice were fused with Sp2/0 cells 17) . The supernatants of hybridoma cells were screened by ELISA using plates coated with purified rhapo F (100 ng/well) and by immunoblotting. Positive hybridoma cells were cloned at least four times by limiting dilution and injected intraperitoneally into pristane-primed Balb/c mice. The IgG fraction was isolated from ascitic fluid using protein A-Sepharose FF (GE Healthcare) according to the manufacturer's instructions, dialyzed at 4 ℃ against PBS, and stored at −80 ℃. The specificities of MAb C2A and MAb 10A5, which were raised against rhapo F from E. coli and CHO cells, respectively, were confirmed by ELISA, and immunoblotting against purified rhapo F. MAb isotype was characterized using the Isotrip mouse monoclonal antiacid agarose column (Qiagen). The recombinant protein was eluted with acetate buffer (50 mM sodium acetate and 0.5 M NaCl, pH 4.5) containing 7 M urea. The purity of purified recombinant human apo F (rhapo F), subjected to SDS-PAGE and visualized by Coomassie brilliant blue (CBB) staining, was determined by gel scanning using the Intelligent Quantifier system (BioImage) as described previously [13] [14] [15] [16] . The apo F cDNA2 was subcloned into the pEF321 mammalian expression vector [13] [14] [15] to yield the pEF321/apo F vector. CHO-K1 cells stably transfected with pEF321/apo F vector were cultured in serum-free medium CHO-S-SFM II (Invitrogen), and the culture medium was collected. Rhapo F was partially purified by metal affinity column chromatography using Taron metal affinity resin (Clontech) followed by anion exchange chromatography using DEAE Sepharose CL-6B (GE Healthcare, Uppsala, Sweden). The purity of rhapo F was confirmed by SDS-PAGE followed by silver staining or immunoblotting. For immunoblotting (Fig. 1A) , rhapo F was detected with anti-Tetra-His antibody (Qiagen) as the primary antibody and horseradish peroxidase-conju- the plate had been washed, 100 μL substrate solution (50 mM citrate-phosphate buffer, pH 5.0) containing 0.4 g/L o-phenylendiamine dihydrochloride and 0.15 ml/L H2O2 was added to each well. After 0.5 h, the reaction was stopped by the addition of 100 μL of 2 mol/L H2SO4. The absorbance was measured at 492 nm with a microplate reader. Purified bacterial rhapo F and pooled culture medium from CHO-K1 cells served as primary and secondary calibrators, respectively.
When purified rhapo F was added to samples of plasma (n = 3) in sufficient amounts to increase the total apo F concentration by 25-100 ng/mL, the final concentrations given by the ELISA averaged 100% (90-116%) of those predicted. The intra-and interassay coefficients of variation of the ELISA were 1.9-3.8% (n = 10) and 2.9-7.8% (n = 10), respectively. No interference with the ELISA was observed with hemo-
. Storage of plasma and serum samples at 4 ℃ for 14 days did not affect the apo F concentration, as determined by ELISA (data not shown).
Assays for CETP, PLTP and Apo J
The intrinsic cholesteryl ester transfer protein (CETP) activity and mass concentration were carried out as previously described 18) . Intrinsic CETP activity was determined as the rate of 3 H-labeled CE transfer from donor HDL to acceptor VLDL/LDL 19) . A plasma sample (95 μL) was incubated with 3 H-labeled HDL (5 μL) for 4 h at 4 ℃ or 37 ℃. After VLDL/LDL was precipitated with 10 μL of 4% phosphotungstate and 2M MgCl2 reagent, the radioactivity of the supernatant was measured. Intrinsic CETP activity was calculated as the difference in radioactivity between samples incubated at 37 ℃ and 4 ℃ as follows; CETP activity (%) = {[(radioactivity at 4 ℃)−(radioactivity at 37 ℃)]/ (radioactivity at 4 ℃)×100}. Each assay was carried out in triplicate. Intrinsic CETP activity correlated significantly with CETP mass (r = 0.180, p = 0.0099), LDL cholesterol (r = 0.431, p＜0.0001) and HDL cholesterol (r =−0.356, p＜0.0001).
Phospholipid transfer protein (PLTP) activity, and the mass concentrations of PLTP and apo J were assessed as described elsewhere 16, 20) . PLTP activity related positively with its mass concentration (r = 0.196, p = 0.0047).
Other Laboratory Methods
Plasma total and HDL cholesterol, triacylglycerol, apo A-I and apo B concentrations were measured with a Hitachi 7450 automated analyzer using commercial kits (Sekisui Medical, Tokyo, Japan). HDL body isotyping kit (Roche Diagnostics, Basel, Switzerland), and was IgG1 for both MAbs C2A and 10A5.
Measurement of Plasma Apo F Concentration
MAb C2A (100 μL of 2 μg/mL solution in PBS) was coated onto a microtiter plate (Nunc Immunoplate II) by incubation at 4 ℃ overnight. The wells were blocked with 200 μL PBS containing 10 g/L BSA for 2 h at room temperature. After the plate had been washed with 300 μL PBS containing 1 g/L Tween 20, 100 μL of the calibrator solution and plasma samples (1:100) diluted with PBS containing 1 g/L Tween 20 and 3 g/L BSA were added and incubated for 2 h at room temperature. After the plate had been washed five times, 100 μL of 0.5 μg/mL biotinylated MAb 10A5 in PBS containing 1 g/L Tween 20 and 3 g/L BSA was added to each well, and the mixture was incubated for 1 h at room temperature. After the plate had been washed five times, 100 μL of 0.1 μg/mL horseradish peroxidase-conjugated streptavidin (Vector Laboratories) was added, and the mixture was incubated for 1 h at room temperature. After jected to SDS-PAGE, MAbs reacted with a single protein (Fig. 1B) , the molecular mass of which (33 kDa under reducing conditions) was similar to that previously reported for human apo F 2)
. Both antibodies reacted with the purified recombinant human apo F protein, and neither inhibited the interaction of the other to apo F coated on a microtiter plate (data not shown), suggesting that they react with different epitopes of apo F protein.
The distribution of apo F in human plasma was analyzed by two methods, ultracentrifugation and size-exclusion chromatography. After ultracentrifugation of pooled plasma, apo F distributed mainly in the subfractions of LDL and HDL3, partly in HDL2 subfraction by SDS-PAGE and Western blotting (Fig. 2) . When human plasma was fractioned by size-exclusion chromatography, and the eluted fractions were analyzed, apo F eluted at a position corresponding to smaller HDL (data not shown).
Standardization of ELISA for Plasma Apo F Concentration
Sandwich ELISA for plasma apo F was established using MAb C2A for capture and biotinylated MAb 10A5 for detection, in which the combination of two MAbs, C2A and 10A5, showed higher absorcholesterol was measured after precipitation of apo B-containing lipoprotein with a commercial reagent containing dextran sulfate, phosphotungstate, and magnesium chloride (Sekisui Medical) 15) . LDL cholesterol concentration was calculated according to Friedewald, Levy, and Friedrickson 21) . Protein content of purified rhapo F was determined by the BCA protein assay kit (Pierce) using BSA as a calibrator. SDS-PAGE was performed by the Laemmli method 22) , and immunoblotting was as described by Towbin, Staehelin, and Gordon 23) . All variables were measured at the BML General Laboratory (Saitama, Japan).
Statistical Analysis
Results are expressed as the mean±SD. ANOVA was used for group comparisons. Correlations were analyzed by Spearman's rank order correlation coefficient. P＜0.05 was considered significant.
Results
Characterization of Anti-Apo F MAbs
Two MAbs specific for apo F were established: MAb C2A and MAb 10A5. Their specificities were examined by SDS-PAGE and immunoblotting under reducing condition. When human plasma was sub- to 250 ng/mL and was suitable for quantifying apo F concentration as low as 6.25 ng/mL. Linearity was also confirmed with serially diluted plasma or serum samples of several concentrations (18.0 to 248.1 ng/ mL) (data not shown). To avoid potential non-linearity caused by very low or high absorbance, the apo F concentrations in plasma samples were measured using several dilutions (1:10 to 1:2,560). At the lowest dilution of 1:10 to 1:20, the results obtained with plasma were not identical to those obtained with the recombinant proteins (Fig. 4) . A 100-fold dilution of plasma sample, in which the diluted aliquot gave an absorbance between 0.5 to 1.2 was chosen for routine use.
To avoid any effects of differences between samples in their lipid or apolipoprotein compositions, the detergent Tween 20 was included in the diluent. We examined several detergents for sample dilution using the Detergent Starter Kit II (Wako Pure Chemical Industries) as previously described 16) . Plasma sample diluted (100-fold) and rhapo F culture medium diluted (10-fold) with PBS containing 1 g/L Tween 20 gave the highest absorbance, but most other detergents gave lower or less absorbance than that in Tween 20; therefore, we chose PBS containing 1 g/L Tween 20 as the sample diluent (data not shown). The intrabance of 1.0 to 2.5 for rhapo F (1.0 μg/mL) and the plasma sample (1:50) than the other combinations. The system showed a dose-dependent response to purified bacterial rhapo F, to CHO culture medium expressing rhapo F, and to plasma, and the reactivity was equal to both bacterial and mammalian rhapo F (Fig. 1) . For calibration of the ELISA, purified bacterial rhapo F was used as the primary calibrator. When subjected to SDS-PAGE and visualized by CBB staining, the purified bacterial rhapo F showed a single major 33 kDa band (Fig. 1A) , in which the purity of protein was ＞95% of total protein as determined by gel scanning using the Intelligent Quantifier system. The protein concentration of this primary rhapo F calibrator, assayed using a bicinchoninic acid protein kit with BSA as calibrator, was typically 54 μg/mL.
To obtain a calibration curve for the ELISA, dilutions of the primary calibrator were made in PBS containing 1 g/L Tween 20 to provide 1.25-25 ng of rhapo F protein per well (1.25-25 μg/mL). When the rhapo F culture medium, as a secondary calibrator, was diluted in PBS containing 1 g/L Tween 20 to cover the apo F concentration range 12.5-250 ng/mL, the curve was identical to that obtained with the primary calibrator (Fig. 3) . The ELISA had linearity up 
The Relationship of Plasma Apo F Concentration to Lipid Transfer Proteins in Healthy Subjects
The relationship of plasma apo F with lipid parameters in healthy subjects is shown in Table 4 . Plasma apo F concentration was correlated negatively with CE transfer (intrinsic CETP) activity determined using intrinsic substrate (r =−0.183, p = 0.0087 for all; r =−0.193, p = 0.0454 for males) but not with CETP mass concentration (Fig. 5) . In addition, it was also related positively with PLTP mass concentration (r = 0.404, p＜0.0001 for all; r = 0.517, p＜0.0001 for males; r = 0.236, p = 0.0208 for females) (Fig. 6) and apo J concentration (r = 0.246, p = 0.0004 for all; r = 0.210, p = 0.0275 for males; r = 0.260, p = 0.0108 for females).
By multiple regression analysis of healthy combined subjects, 32% of variance in intrinsic CETP activity was explained by the covariates of CETP mass, apo F and triglyceride concentration. Of these variables, CETP mass and triglyceride were most strongly associated with intrinsic CETP activity (p＜0.0001 and interassay variation in the ELISA was 1.9-3.8% and 2.9-7.8%, respectively.
Plasma Apo F Concentrations in Healthy Subjects
Plasma apo F concentrations in healthy subjects are presented in Table 3 . The average apo F concentration was 12.5±3.1 μg/mL, ranging from 6.1 to 22.0 μg/mL in females and from 4.7 to 21.6 μg/mL in males, being higher in females than in males (p＜ 0.005). In all healthy subjects combined (both sexes pooled), plasma apo F concentrations was positively correlated with HDL cholesterol (r = 0.362, p＜0.0001 for all; r = 0.452, p＜0.0001 for males; r = 0.202, p = 0.0059 for females) and apo A-1 (r = 0.383, p＜ 0.0001 for all; r = 0.457, p＜0.0001 for males; r = 0.246, p = 0.0159 for females), and negatively correlated with triglyceride (r =−0.221, p＜0.0001 for all; r =−0.302, p＜0.0001 for males) ( Table 4) . In females but not males, apo F concentration was related positively with total cholesterol (r = 0.237, p = 0.0013), LDL cholesterol (r = 0.197, p = 0.0073) and apo B (r = 0.247, p = 0.0156). In males, apo F concentration was negatively related with LDL cholesterol (r =−0.302, Spearman's correlation coefficient (r). Numbers in bold show significant correlation.
Plasma Apo F Concentrations in Hypertriglyceridemic Subjects
We also measured apo F concentrations in hypertriglyceridemic subjects. Apo F concentrations in hypertriglyceridemic subjects were 10.2±3.3 μg/mL for males and 10.7±2.6 μg/mL for females, respectively, and were significantly lower than those of for both), while apo F (p = 0.0191) was also a significant independent contributor in the model; however, apo F was not a significant contributor when analyzed for each gender (p = 0.17 for males and p = 0.0747 for females). ApoF (µg/mL) PLTP activity (µmol/mL/h) subjects by competitive ELISA using polyclonal antibodies raised against recombinant LTIP-GST fusion protein. Similarly, we have previously observed an inconsistency in quantity 16) . This is probably related at least in part to the relatively high affinity of our calibrator of purified recombinant apo F from CHO cells. A second consideration concerns the dilution of the plasma sample used in the assay studied. In our assay, a 100-fold dilution of plasma was used routinely, whereas in addition to the longer incubation time (overnight), they used a lower dilution (20-fold). Relatively low dilutions with a long incubation might lead to non-specific binding of apo F to the plate, resulting in the true concentration being over-estimated. A non-methodological factor that might have contributed to the differences between the concentrations observed in different studies is that of sample size. The previous study was smaller than ours. Another possibility may be the protein concentration of the calibrator. In our assay, a primary calibrator of rhapo F from E. coli (the purity of ＞90%) reacted dose-dependently with rhapo F from CHO cells and the plasma sample (Fig. 4) ; however, they determined the protein concentration by multiple quantitative immunoblotting using the Positope as a calibrator in combination with His-tag antibody 2) . This may overestimate and/or underestimate due to the affinity of the antibody. Our study is also the first in Japanese subjects, raising the possibility of an ethnic effect and/ or disease association on apo F concentration; however, the discrepancy should be clarified further.
In the present study, a higher apo F concentration in females than in males was observed in healthy subjects. The opposite observation has been reported in normolipidemic subjects 2) . This may be due to the subjects studied. In the previous report, the studied subjects over 60 years old or with hypertriglyceridemia had lower apo F concentration (56% of normolipidemic subjects) 2) . In this study, triglyceride was 2-fold higher in males, and 27% of males had higher triglyceride (＞150 mg/dL). Increased triglyceride may partly cause a decrease of apo F levels by increased plasma clearance of apo F 2)
. The other possibility was the age of subjects studied. The mean age of subjects was over 60 years old in the previous study. In our study, the higher apo F in females was still significant in the subjects aged over 45 years old (yrs) (11.8±3.7 μg/mL vs. 14.0±3.5 μg/mL, p = 0.0027) but not in those under 45 yrs (12.1±3.1 μg/mL vs. 12.7±2.6 μg/mL, p = 0.08). In addition, healthy females below 45 years old (91%) had lower apo F concentration than those over 45 yrs (12.7±2.6 μg/mL vs. 14.0±3.5 μg/mL, p = 0.0250), but this was not the case in healthy males healthy controls for each gender (p = 0.0072 for males and p = 0.0016 for females, respectively) ( Table 3) . In hypertriglyceridemic males, but not females, apo F related positively with total cholesterol (r = 0.229, p = 0.0033) and LDL and HDL cholesterol (r = 0.180, p = 0.0209 and r = 0.340, p＜0.0001, respectively), and negatively with triglyceride (r =−0.193, p = 0.0132). Similar to healthy subjects, apo F was positively related with PLTP mass in hypertriglyceridemic male subjects (r = 0.391, p＜0.0001 for all; r = 0.430, p＜0.0001 for males; r = 0.139, p = 0.31 for females).
Discussion
There have been few studies of the relation of apo F to lipoprotein metabolism in humans. For a better understanding of the function of apo F, there is a need for reliable and sensitive methods for its quantification. To this end, we prepared a series of MAbs against recombinant apo F expressed by E. coli and CHO cells, and used them to develop a sandwich ELISA. By SDS-PAGE and immunoblotting, both MAbs recognized a single protein in recombinant apo F and human plasma of ~33 kDa under reducing conditions, indicating that they reacted with a linear epitope of apo F protein. This is the same as previous reports of plasma apo F 2, 8) . This ELISA was suitable for assaying plasma apo F concentration in the range of 0.6-25 μg/mL. No differences in the dilution curves were observed between recombinant apo F purified from E. coli and CHO cells (primary and secondary calibrators) and human plasma. Intra-and inter-assay coefficients of variation were ＜5%. Our results indicated that our ELISA is specific, accurate, reproducible and sufficiently sensitive for a wide range of applications. Our assay is more reliable, sensitive and reproducible than previously reported assays 2, 12, 24) , and has a wider range of linearity (0.6-25 μg/mL vs. 0.97-15.56 μg/mL) than the competitive ELISA of Morton et al. 2) . Sandwich ELISAs are generally easier to perform with good inter-assay precision than electroimmunoassay and competitive ELISAs, as the latter requires purified apo F.
We used our ELISA to measure the plasma apo F concentration in 397 Japanese healthy and 221 hypertriglyceridemic subjects. No healthy subject was taking lipid-lowering medication. The plasma apo F concentrations we observed in healthy subjects tended to be lower than those observed by others 2, 24) . McConathy et al. 24) , using an electroimmunosaasy, estimated plasma apo F concentration of 27 μg/mL. Morton et al. 2) reported that plasma apo F concentration was 83.5±4.8 μg/mL (mean±SD) in 76 normolipidemic Furthermore, we observed a positive relationship between apo F and PLTP mass levels in healthy and hypertriglyceridemic male subjects. As described above, plasma apo F in human exists predominantly in the HDL3 fraction 7, 8) . In humans, most plasma PLTP associated with HDL3 particles exists as an inactive form 21, 27) . The mechanism of inactivation of PLTP remains unclear. By the quantitative trait locus (QTL) analysis in mice, Apof has been found to be a candidate gene affecting PLTP activity 28) . As both proteins are quite similar in particle size and complex with the same lipoprotein particles, apo F has an inhibitory effect on not only CETP activity but also PLTP activity 10) . It is hypothesized that apo F may interact and complex with PLTP-containing particles, resulting in inactivation of PLTP activity. The precise mechanism should be examined further.
We have developed a reliable and accurate sandwich ELISA for the concentration of plasma apo F. Our ELISA system might be a useful tool to determine the clinical significance in subjects with dyslipidemia, metabolic syndrome and lipoprotein metabolism, including reverse cholesterol transport.
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